Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Rheumatic Aortic Stenosis
Original Research | By A Mentias, M Saad ,MY Desai et al.
BACKGROUND - Patients with rheumatic aortic stenosis (AS) were excluded from transcatheter aortic valve replacement (TAVR) trials. OBJECTIVES - The authors sought to examine outcomes with TAVR versus surgical aortic valve replacement (SAVR) in patients with rheumatic AS, and versus TAVR in nonrheumatic AS. METHODS - The authors identified Medicare benef...
Review Article | By ATL Fiolet, TSJ Opstal, JH Cornel et al.
Review Article | By M Verdoia, F Negro, G De Luca et al.
BACKGROUND - Drug-coated balloons (DCB) have shown promising results for the percutaneous treatment of de novo and restenotic lesions, involving both the coronary and femoropopliteal district. However, clinical outcomes data associated with the use of this device are still unclear, with potential warnings on increased mortality being raised from initial studies. We aimed at performing an updated and comprehensive met...
Original Research | By EM DeFilippis, HGC Van Spall.
Please click on "Article Link" to get access to this article.
Original Research | By F Namazi , P van der Bijl , F Fortuni et al.
OBJECTIVES - The purpose of this study was to investigate the prognostic implications of the ratio of mitral regurgitant volume (RVol) to left ventricular (LV) end-diastolic volume (EDV) in patients with significant secondary mitral regurgitation (MR). BACKGROUND - Quantification of secondary MR remains challenging, and its severity can be over- or underestimated when using the proximal isovelocity ...
Antithrombotic Management of Elderly Patients With Coronary Artery Disease
Review Article | By P Capranzano, DJ Angiolillo.
Antithrombotic therapy represents the mainstay of treatment in patients with coronary artery disease (CAD), including elderly patients who are at increased risk for ischemic recurrences. However, the elderly population is also more vulnerable to bleeding complications. Numerous mechanisms, including abnormalities in the vasculature, thrombogenicity, comorbidities, and altered drug response, contribute to both increased thrombotic and bleed...
Clinical Trial | By J Chandrasekhar, P Anthopoulos, GD Dangas et al.
BACKGROUND - Acute kidney injury (AKI) is not uncommon in patients undergoing transcatheter aortic valve replacement (TAVR). OBJECTIVE - We examined the incidence, predictors, and outcomes of AKI from the BRAVO 3 randomized trial. METHODS - The BRAVO-3 trial included 802 patients undergoing transfemoral TAVR randomized to bivalirudin vs. unfractionated hepar...
Long-Term Outcomes of Patients With Late Presentation of ST-Segment Elevation Myocardial Infarction
Original Research | By KH Cho , XY Han, and on behalf of the KAMIR-NIH Investigators.
BACKGROUND - Real-world data on baseline characteristics, clinical practice, and outcomes of late presentation (12 to 48 h of symptom onset) in patients with ST-segment elevation myocardial infarction (STEMI) are limited. OBJECTIVES - This study aimed to investigate real-world features of STEMI late presenters in the contemporary percutaneous coronary intervention (PCI) era. ME...
Consensus | By RHJA Slart, MC Williams, LE Juarez-Orozco et al.